The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Biomarker Testing for Patients With Advanced Non–Small Cell Lung Cancer: Real-World Issues and Tough Choices
Abstract
Over the last decade, the treatment of patients with advanced non–small cell lung cancer (NSCLC) has become reliant on tissue and/or blood biomarkers to help guide treatment decisions. There are now multiple biomarker-defined patient subgroups, with evidence showing that treatment with targeted therapies has superior clinical outcomes when compared with traditional cytotoxic chemotherapy. However, rapid change in the field of precision oncology brings with it the challenge of translating recommendations into clinical practice. In this review, we discuss the major guidelines recommending biomarker testing in NSCLC, as well the logistical challenges to applying these guidelines to patients with NSCLC both in the United States and worldwide. The techniques commonly used for biomarker testing will be discussed, both for tissue- and blood-based biomarkers. Finally, we discuss the challenge of interpreting the results of biomarker testing and using these results to guide treatment decisions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
NTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,485
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318290868f · Cited by 1,280
Gandara, D. R., Paul, S. M., Kowanetz, M., Schleifman, E., Zou, W., Li, Y., Rittmeyer, A., Fehrenbacher, L., Otto, G., Malboeuf, C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0134-3 · Cited by 1,157
Self-citationMateo, J., Chakravarty, D., Dienstmann, R., Jezdic, S., Gonzalez-Perez, A., Lopez-Bigas, N., Ng, C. K. Y., Bedard, P. L., Tortora, G., Douillard, J.-Y., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy263 · Cited by 815
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Rolfo, C., Mack, P. C., Scagliotti, G. V., Baas, P., Barlesi, F., Bivona, T. G., Herbst, R. S., Mok, T. S., Peled, N., Pirker, R., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.030 · Cited by 660
Self-citationLindeman, N. I., Cagle, P. T., Aisner, D. L., Arcila, M. E., Beasley, M. B., Bernicker, E. H., Colasacco, C., Dacic, S., Hirsch, F. R., Kerr, K., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.12.001 · Cited by 645
Self-citationArcila, M. E., Oxnard, G. R., Nafa, K., Riely, G. J., Solomon, S. B., Zakowski, M. F., Kris, M. G., Pao, W., Miller, V. A., & Ladanyi, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2277 · Cited by 574
Self-citationYang, J. C.-H., Ahn, M.-J., Kim, D.-W., Ramalingam, S. S., Sequist, L. V., Su, W.-C., Kim, S.-W., Kim, J.-H., Planchard, D., Felip, E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.3223 · Cited by 571
Kalemkerian, G. P., Narula, N., Kennedy, E. B., Biermann, W. A., Donington, J., Leighl, N. B., Lew, M., Pantelas, J., Ramalingam, S. S., Reck, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.7293 · Cited by 492
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018
Ettinger, D. S., Aisner, D. L., Wood, D. E., Akerley, W., Bauman, J., Chang, J. Y., Chirieac, L. R., D'Amico, T. A., Dilling, T. J., Dobelbower, M., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0062 · Cited by 463
Selective RET kinase inhibition for patients with RET-altered cancers
Subbiah, V., Velcheti, V., Tuch, B. B., Ebata, K., Busaidy, N. L., Cabanillas, M. E., Wirth, L. J., Stock, S., Smith, S., Lauriault, V., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy137 · Cited by 425
KRAS-Mutant non-small cell lung cancer: From biology to therapy
Ferrer, I., Zugazagoitia, J., Herbertz, S., John, W., Paz-Ares, L., & Schmid-Bindert, G. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.07.013 · Cited by 311
Ellison, G., Zhu, G., Moulis, A., Dearden, S., Speake, G., & McCormack, R. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201194 · Cited by 301
Wu, Y.-L., Planchard, D., Lu, S., Sun, H., Yamamoto, N., Kim, D.-W., Tan, D. S. W., Yang, J. C.-H., Azrif, M., Mitsudomi, T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy554 · Cited by 291
HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers
Li, B. T., Ross, D. S., Aisner, D. L., Chaft, J. E., Hsu, M., Kako, S. L., Kris, M. G., Varella-Garcia, M., & Arcila, M. E. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.10.025 · Cited by 286
Kazandjian, D., Blumenthal, G. M., Chen, H.-Y., He, K., Patel, M., Justice, R., Keegan, P., & Pazdur, R. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0241 · Cited by 286
Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer
Niederst, M. J., & Engelman, J. A. (2013) · Science Signaling · doi:10.1126/scisignal.2004652 · Cited by 263
Pan, Q., Pao, W., & Ladanyi, M. (2005) · The Journal of Molecular Diagnostics · doi:10.1016/s1525-1578(10)60569-7 · Cited by 248
Odogwu, L., Mathieu, L., Blumenthal, G., Larkins, E., Goldberg, K. B., Griffin, N., Bijwaard, K., Lee, E. Y., Philip, R., Jiang, X., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0642 · Cited by 218
Gutierrez, M. E., Choi, K., Lanman, R. B., Licitra, E. J., Skrzypczak, S. M., Pe Benito, R., Wu, T., Arunajadai, S., Kaur, S., Harper, H., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.04.004 · Cited by 208
Reungwetwattana, T., Liang, Y., Zhu, V., & Ou, S.-H. I. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2016.11.011 · Cited by 169
Presley, C. J., Tang, D., Soulos, P. R., Chiang, A. C., Longtine, J. A., Adelson, K. B., Herbst, R. S., Zhu, W., Nussbaum, N. C., Sorg, R. A., et al. (2018) · JAMA · doi:10.1001/jama.2018.9824 · Cited by 140
Rizvi, N. A., Cho, B. C. C., Reinmuth, N., Lee, K. H., Ahn, M., Luft, A. V., van den Heuvel, M. M., Cobo, M., Smolin, A., Vicente, D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy511.005 · Cited by 92
Lee, K. H., Tsao, M., Kambartel, K.-O., Isobe, H., Huang, M.-S., Barrios, C. H., Khattak, A., de Marinis, F., Kothari, S., Arunachalam, A., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202865 · Cited by 89
Enewold, L., & Thomas, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156728 · Cited by 80
Gray, P. N., Dunlop, C. L. M., & Elliott, A. M. (2015) · Cancers · doi:10.3390/cancers7030837 · Cited by 62
Cheema, P. K., Menjak, I. B., Winterton-Perks, Z., Raphael, S. J., Cheng, S. Y.-S., Verma, S., Muinuddin, A., Freedman, R. L., Toor, N., Perera, J., et al. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2016.014019 · Cited by 58
Miller, T. E., Yang, M., Bajor, D. J., Friedman, J. D., Chang, R. Y. C., Dowlati, A., Willis, J. E., & Sadri, N. (2018) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205396 · Cited by 50
What Can Be Done to Improve Research Biopsy Quality in Oncology Clinical Trials?
Ferry‐Galow, K. V., Datta, V., Makhlouf, H. R., Wright, J., Wood, B. J., Levy, E. B., Pisano, E. D., Tam, A. L., Lee, S. I., Mahmood, U., et al. (2018) · Journal of Oncology Practice · doi:10.1200/jop.18.00092 · Cited by 47
Pennell, N. A., Mutebi, A., Zhou, Z., Ricculli, M. L., Tang, W., Wang, H. H., Guérin, A., Arnhart, T., Culver, K. W., & Otterson, G. A. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.9031 · Cited by 45
Self-citationVelcheti, V., Kim, E. S., Mekhail, T. M., Dakhil, C. S. R., Stella, P. J., Shen, X., Hu, S., Paul, S. M., Shames, D. S., Yun, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.12001 · Cited by 43
Shen, C., Kehl, K. L., Zhao, B., Simon, G. R., Zhou, S., & Giordano, S. H. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.11.002 · Cited by 38
Cheng, Y., Wang, Y., Zhao, J., Liu, Y., Gao, H., Ma, K., Zhang, S., Xin, H., Liu, J., Han, C., et al. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12859 · Cited by 38
Zhou, Q. H., Song, Y., Zhang, X., Chen, G., Zhong, D., Yu, Z., Yu, P., Zhang, Y.-P., Chen, J., Hu, Y., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3451-x · Cited by 31
MacLeod, A. K., Lin, D., Huang, J. T.-J., McLaughlin, L. A., Henderson, C. J., & Wolf, C. R. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3555 · Cited by 29
Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance
Heydt, C., Michels, S. Y. F., Thress, K. S., Bergner, S., Wolf, J., & Buettner, R. (2018) · Oncotarget · doi:10.18632/oncotarget.24624 · Cited by 28
Borsu, L. A., Intrieri, J., Thampi, L. M., Yu, H. A., Riely, G. J., Nafa, K., Chandramohan, R., Ladanyi, M., & Arcila, M. E. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.07.004 · Cited by 22
Self-citationMolecular testing patterns in metastatic non-small cell lung cancer.
MacLean, E. A., Louder, A. M., Saverno, K. R., Smith, G. L., Mardekian, J., Brunis, C., Ward, M., Sweetman, R. W., & Pasquale, M. K. (2016) · PubMed · Cited by 21
EGFR Mutation Testing: Changing Patterns of Molecular Testing in Brazil
Palacio, S., Pontes, L. D. B., Prado, E., Arshad, J., Ali, R. A., Piha, T., Bacchi, C. E., Mudad, R., & Junior, G. L. L. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0254 · Cited by 18
Melosky, B. L., Popat, S., & Gandara, D. R. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.05.019 · Cited by 10
Self-citationJohnson, M. L., Pennell, N. A., & Borghaei, H. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201231 · Cited by 6
Self-citation
Cited by
Current and Future Development in Lung Cancer Diagnosis
Nooreldeen, R., & Bach, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168661 · Cited by 931
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
Tan, A. C., & Tan, D. S. W. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01626 · Cited by 779
Imyanitov, E. N., Iyevleva, A. G., & Levchenko, E. V. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103194 · Cited by 526
Planchard, D., Besse, B., Groen, H. J. M., Hashemi, S. M. S., Mazieres, J., Kim, T. M., Quoix, E., Souquet, P.-J., Barlesi, F., Baik, C., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.08.011 · Cited by 272
Dysbiosis of the Gut Microbiome Is Associated With Tumor Biomarkers in Lung Cancer
Liu, F., Li, J., Guan, Y., Lou, Y., Chen, H., Xu, M., Deng, D., Chen, J., Ni, B., Zhao, L., et al. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.35980 · Cited by 197
Metadata
- Authors
- Pennell, N. A., Arcila, M. E., Gandara, D. R., & West, H.
- Venue
- American Society of Clinical Oncology Educational Book
- Published
- 2019-05
- Volume
- 39
- Issue
- 39
- Pages
- 531-542
- ISSN
- 1548-8748 (ISSN-L)
- 1548-8756
- OpenAlex
- W2946670461
- Cited by
- 310
- References
- 55
- FWCI
- 26.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.